Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

6014 - Levels of circulating fibroblast growth factor (FGF) 23 and prognosis of cancer patients with bone metastasis

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research

Presenters

André Mansinho

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

A.B. Mansinho1, A.R. Ferreira1, S. Casimiro2, I. Alho2, I. Vendrell1, A.L. Costa1, R.T.D. Sousa1, C.D. Abreu1, C. Pulido3, D. Macedo1, T. Pacheco1, L. Correia4, L. Costa1

Author affiliations

  • 1 Medical Oncology, Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), 1649-035 - Lisbon/PT
  • 2 Lcosta Lab, Instituto de Medicina Molecular, 1649-035 - Lisbon/PT
  • 3 Oncology, Hospital da Luz, 1500-650 - Lisbon/PT
  • 4 Pathology, Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), 1649-035 - Lisbon/PT
More

Resources

Abstract 6014

Background

The FGF signaling network plays a key role in tumorigenesis and is recognized as a potential therapeutic target. FGF23 is predominately expressed in bone osteocytes and can act as an autocrine, paracrine and/or endocrine growth factor in cancer. In this study, we aimed to assess the role of circulating FGF23 levels in the prognosis of cancer patients with bone metastases.

Methods

This study included a cohort of 112 patients with cancer (63% breast;16% prostate) and metastatic bone disease treated with bone targeting agents (BTA), in which serum baseline FGF23 was quantified by ELISA and further dichotomized in two groups (FGF23high and FGF23low). Cut-off was defined by mean + one standard deviation. The association of FGF23 with overall survival (OS) and with time to skeletal related events (TTSRE) was investigated. Time to event outcomes was calculated using the Kaplan-Meier method and tested using univariate/multivariate Cox regression models controlling for established prognostic factors across patients with solid tumors and bone metastases: extra-bone involvement, urinary N-terminal telopeptide (uNTX), presence of bone fractures, and calcemia.

Results

Mean FGF23 was 38.16 ± 26.15 pg/mL (interquartile range [IQR] 19.77-50.72). 16.8% of patients were classified as FGF23high (n = 19). Baseline characteristics were balanced between groups, except for the median uNTX level, which was higher in the FGF23high group (824.30 vs 118.02 nmol BCE/mmol creatinine, p = 0.040). Median time from beginning of BTA was similar between groups (1.28 vs 1.10 months, p = 0.161). After a median follow-up of 26.0 months (IQR 13.0-47.0), median OS was 34.4 months in the FGF23low group and 12.2 months in the FGF23high group (multivariate HR 0.18, 95% CI 0.07 – 0.44, p = 0.001; univariate p = 0.001). As a continuous variable, FGF23 at baseline kept its prognostic association (p = 0.001). Patients with FGF23low status at baseline had a longer TTSRE (13.0 vs 2.0 months, p = 0.04).

Conclusions

In this exploratory cohort, patients in the FGF23low group had a longer OS and TTSRE. Further studies are warranted to define its role as a prognostic biomarker and as a potential predictor of response to drugs targeting the FGF axis.

Clinical trial identification

Legal entity responsible for the study

Instituto de Medicina Molecular.

Funding

Has not received any funding.

Editorial Acknowledgement

Joana Cavaco Silva - Medical Writer (Medical Oncology Department - Hospital de Santa Maria - Centro Hospitalar Lisboa Norte).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.